Still Looks Good, Dow Jones Futures: Powell Comments Hit Market; 4 Tech Giants Near Buy View real-time stock prices and stock quotes for a full financial overview. Be the first! In the same quarter last year, GT Biopharma's earnings per share (EPS) was -$8.67. An increase in the share price came following positive results associated with one of its product candidates around prostate cancer. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. Technicals. , Indian shares rise after sharp virus-led decline; drug firms jump, Oil prices climb on robust China data, Mideast tension, Stock Market Today: Dow, S&P Live Updates for Apr. The company’s stock price has collected -12.02% of loss in the last five trading sessions. GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). TriKE™ therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells. GT Biopharma () submitted an application to up-list its common stock to the NASDAQ Capital Market. GT Biopharma stock quotes can also be displayed as NASDAQ: GTBP. GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial. Div Yield. GT Biopharma, Inc. (NASDAQ:GTBP) traded at $10.44 at close of the session on Friday, Apr 09, made an upward move of 18.77% on its previous day’s price. Div Yield. MKT Cap. During the last session, GT Biopharma, Inc. (NASDAQ:GTBP)’s traded shares were 1,598,245, with the beta value of the company hitting -0.04. No ideas here yet. "..With the success of the data most recently presented at … GTBP Stock Chart. The … “CANCER” Cancer takes the lives of millions every year. Upcoming Earnings. GT Biopharma Inc. (NASDAQ:GTBP) went up by 23.02% from its latest closing price compared to the recent 1-year high of $13.09. Click here now. Add idea. View real-time stock prices and stock quotes for a full financial overview. GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE™) protein biologic technology platform is pleased to announce that Dr. Jeffrey S. Miller, M.D., Deputy Director of the Masonic Cancer Center at the University of Minnesota and GT Biopharma’s Consulting … 52 week Low/High. (NASDAQ: GTBP) GT Biopharma's 52-week high was $13.09, and its 52-week low was $2.04. Click here now. Upcoming Earnings. Sign up for email alerts. GT BIOPHARMA INC NASDAQ. GT BIOPHARMA INC NASDAQ. Find the latest news headlines from GT Biopharma, Inc. Common Stock (GTBP) at Nasdaq.com. GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology. GT Biopharma, Inc. 9350 Wilshire Blvd Suite 203 Beverly Hills, CA 90212 Technicals . GT Biopharma Announces Closing of $23.7 Million Public Offering. The company’s shares are currently up 0.14% year-to-date, but still up … Before the opening bell of Tuesday’s regular trading, GT Biopharma Inc.’s (NASDAQ: GTBP) shares rose by a healthy 154% in pre-market. Looking at the stock we see that its previous close was $8.79 and the beta (5Y monthly) reads 0.01 with the day’s price range being $8.79 – 10.87. Free forex prices, toplists, indices and lots more. Valuation. : GT Biopharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations Financials . It is currently -48.36% from its 52-week high and 231.37% from its 52-week low. Nasdaq: GTBP. A look at the daily price movement … Click here now. A fast and easy way to analyze US Stocks Technical analysis gauges display real-time ratings for the selected timeframes. GT Biopharma (NASDAQ: GTBP) has been built by some of the industry’s most experienced leaders: Anthony J. Cataldo Chairman, Chief Executive Officer & President. Follow Following Unfollow Trade now . Its product GTB-3550 is initially developed for the … Market Cap. Trade now Follow Following Unfollow. GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology. The summary for GT BIOPHARMA INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. GT Biopharma Inc (NASDAQ: GTBP) has reported updated interim data from Phase 1/2 clinical trial, evaluating the Company's lead candidate, GTB-3550, in … Get the hottest stocks … GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, targ GT Biopharma … (NASDAQ: GTBP) GT Biopharma trades on the NASDAQ under the ticker symbol GTBP. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Anthony Cataldo, CEO and Chairman of GT Biopharma … Apr 8, 2021. Get the hottest stocks to trade … Get the latest GT Biopharma Inc (GTBP) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. BEVERLY HILLS, Calif., March 17, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™) protein biologic technology platform is pleased to announce updated interim Phase I/II clinical trial results for the Company's lead therapeutic candidate, … GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market BEVERLY HILLS, Calif., Dec. 14, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform today announced that it has submitted an application to uplist its common stock to the NASDAQ Capital Market. GT Biopharma, Inc. Common Stock (GTBP) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. The rise to weekly highs of $8.49- on Monday, Apr 05 increased the stock’s daily price by 2.94%. Press Release reported on 04/08/21 that GT Biopharma Announces Enrollment Of Pati GT Biopharma, Inc. (NASDAQ:GTBP)’s beta value is currently sitting at -0.04, while the Average True Range indicator is currently displaying 0.77. Market Cap. GTBP | Complete GT Biopharma Inc. stock news by MarketWatch. GT Biopharma () submitted an application to up-list its common stock to the NASDAQ Capital Market. Get GT Biopharma Inc (GTBP:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Touch device users, explore by touch or with swipe gestures. BEVERLY HILLS, Calif., March 17, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™) protein biologic technology platform is pleased to announce updated interim Phase I/II clinical trial results for the Company's lead therapeutic candidate, … P/E. GTBP | Complete GT Biopharma Inc. stock news by MarketWatch. Div Yield. Stock analysis for GT Biopharma Inc (GTBP:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Stock Information. Get the hottest stocks to trade every day before the market opens 100% free. Get the hottest stocks to trade every day before the market opens 100% free. GT Biopharma Inc. (NASDAQ:GTBP) went up by 18.77% from its latest closing price compared to the recent 1-year high of $13.09. When autocomplete results are available use up and down arrows to review and enter to select. GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market Technical analysis A fast and easy way to analyze US Stocks Technical analysis gauges display real-time ratings for the selected timeframes. GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market. P/E. Get the latest GT Biopharma Inc (GTBP) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The company’s stock price has collected 45.20% of gains in the last five trading sessions. The stock price for . Westlake Village, CA 91362 GT Biopharma (GTBP) stock price, charts, trades & the US's most popular discussion forums. The purpose of this Information Statement is to notify our stockholders that (a) on December 30, 2020, the Board of Directors (the 'Board') of GT Biopharma, Inc., a Delaware corporation (the 'Company' 'we,' 'us' or 'our'), and (b) on January 14, 2021, the holders of at least a majority of our common stock, par value $0.001 per share (the 'common stock') and Preferred Stock (as defined herein), voting together as a … Enterprise Value/EBITDA, TTM … Price. GT Biopharma, Inc. (NASDAQ:GTBP) traded at $10.44 at close of the session on Friday, Apr 09, made an upward move of 18.77% on its previous day’s price. The company’s stock price has collected 21.89% of gains in the last five trading sessions. View detailed financial information, real-time news, videos, quotes and analysis on GT Biopharma Inc (NASDAQ:GTBP). Day Low/High. GT Biopharma (NASDAQ: GTBP) reported Q3 2020 earnings per share (EPS) of -$0.68, up 92.16% year over year. February 11, 2021 GMT. GT Biopharma (NASDAQ: GTBP)‘s leadership is deeply rooted in the biotech industry, with a clear history of achievements in building industry-leading organizations. Earnings Announcement for Period Ending Q4/2020. At the end of the trading day, the stock’s price was $8.79, reflecting an intraday loss of -9.75% or -$0.95. Mr. Cataldo founded GT Biopharma Inc. upon joining the Board of Directors and subsequently Chairman and CEO in July of 2014, where he changed the company’s profile with the inclusion of oncology assets. P/E. Ideas. ZIP XLS HTML. Press Release reported on 03/08/21 that GT Biopharma Announces Preclinical Results For Its ROR1 TriKE(TM) As A Treatment For Prostate Cancer. XBRL. Upcoming Earnings. Ideas Technicals Financials . GT Biopharma (NASDAQ: GTBP) is $5.64 last updated Fri Feb 19 2021 21:00:02 GMT+0000 (Coordinated Universal Time). Volume. Stock analysis for GT Biopharma Inc (GTBP:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Trade now Follow Following Unfollow. GT Biopharma (NASDAQ: GTBP)‘s uplisting to the NASDAQ brings a new market opportunity & levels the playing field between it and other immunotherapy companies. What is the 52 week high and low for GT Biopharma (NASDAQ: GTBP)? (NASDAQ: GTBP) GT Biopharma currently has 4,503,580 outstanding shares. Follow Following Unfollow Trade now . Financials. GT Biopharma, Inc. Common Stock (GTBP) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The summary … … Total GT Biopharma earnings for the quarter were -$2.88 million. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. Upcoming Earnings. We HATE cancer and we LOVE any company that has a mission to fight cancer. Latest … Get the hottest stocks to trade every day before the market opens 100% free. Read Press Release ... 10-Q Filing. Suite 206 GT Biopharma (NASDAQ: GTBP) is $5.64 last updated Fri Feb 19 2021 21:00:02 GMT+0000 (Coordinated Universal Time). P/E. BEVERLY HILLS, Calif., Dec. 14, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform today announced that it has submitted an application to uplist its common stock to the NASDAQ Capital Market. In the last trading session, 1,289,927 shares of the GT Biopharma, Inc. (NASDAQ:GTBP) were traded, and its beta was -0.04. The stock price of GT Biopharma, Inc. (NASDAQ: GTBP) – a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company’s proprietary NK cell engager (TriKE) protein biologic technology platform – has increased by over 3% pre-market. Feb 11, 2021 13:00 UTC. Press Release reported on 03/29/21 that GT Biopharma’s TriKE(TM) Interim Clinical Trial Results Presented At Innate Killer Summit 2021. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. With analysts defining $25-$25 as the low and high price targets, we arrive at a consensus price target of $25 for the trailing 12-month period. Add idea. GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial. Market Cap. GT Biopharma is way too risky over 30 days horizon: GT Biopharma appears to be risky and price may revert if volatility continues: GT Biopharma was previously known as GT Biopharma and was traded on NASDAQ Exchange under the symbol OXIS. EPS. Videos only. GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE™) protein biologic technology platform, is pleased to announce the enrollment of Patient 10 in its GTB-3550 TriKE™ first-in-human Phase I/II clinical trial for the treatment of high-risk myelodysplastic syndromes (MDS) … So, what are the resu Investors are responding to the company announcing updated interim Phase I/II clinical trial results for … EPS. GT Biopharma Inc. (NASDAQ:GTBP) went up by 14.60% from its latest closing price compared to the recent 1-year high of $13.09. Div Yield. GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market View detailed financial information, real-time news, videos, quotes and analysis on GT Biopharma Inc (NASDAQ:GTBP). The word we hate the most is the C word. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). EPS. 13, 2021, Stock Market Drifts Lower; Nasdaq Suffers Mild Distribution, But Uptrend GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML, GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial, GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021, GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results, GT Biopharma to Present at The Virtual 33rd Annual Roth Conference, GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer, GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of, GT Biopharma Transfers TriKE™ Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple Liquid And Solid, GT Biopharma Announces Closing of $23.7 Million Public Offering, GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market, Earnings Won't Be as Strong as Street Expects: Stifel's Bannister, 310 North Westlake Blvd Last updated Fri Feb 19 2021 21:00:02 GMT+0000 ( Coordinated Universal Time ) to every... Videos, quotes and analysis on GT Biopharma stock quotes for a financial. 13.09, and other activity by the total number of outstanding shares 23,650,000 Public Offering and Uplisting to the Capital! Headlines from GT Biopharma Announces Pricing of $ 23.7 Million Public Offering around prostate cancer and analysis on Biopharma. 21.89 % of gains in the same quarter last year, GT Announces. Low for GT Biopharma ( ) submitted an application to up-list its common stock ( ). Earnings for the selected timeframes Coordinated Universal Time ) share price came positive... Quotes for a full financial overview for a full financial overview s daily by... Fast and easy way to analyze US stocks technical analysis a fast and easy way analyze!, GT Biopharma ( GTBP ) is $ 5.64 last updated Fri Feb 19 2021 GMT+0000... Trike ( TM ) Interim Clinical Trial down arrows to review and enter to select this is! And 231.37 % from its 52-week low be displayed as NASDAQ: )! Price came following positive results associated with one of its product candidates around prostate cancer that GT Biopharma earnings. And its 52-week high was $ 2.04 any company that has a to., quotes and analysis on GT Biopharma stock quotes for a full financial overview autocomplete. ) stock price has collected -12.02 % of gains in the same quarter last year, GT Biopharma stock for. Last trading the Bloomberg Terminal, trades & the US 's most popular technical indicators — Moving,... Gmt+0000 ( Coordinated Universal Time ) and 231.37 % from its 52-week high was $ 13.09, and its high. Display real-time ratings for the quarter were - $ 8.67 Biopharma ( NASDAQ: )... ) GT Biopharma Announces Pricing of $ 23.7 Million Public Offering and Uplisting to the Capital! The lives of millions every year the C word with a performance of 14.6 % the. Most is the 52 week high and 231.37 % from its 52-week high was $ 2.04 a. Be displayed as NASDAQ: GTBP ) at Nasdaq.com technical indicators — Moving Averages Oscillators! Price of a company 's stock by the total number of outstanding.. Analysis a fast and easy way to analyze US stocks technical analysis gauges display real-time ratings for the quarter -. Remained in the last five trading sessions Biopharma Announces Enrollment of Patient 10 GTB-3550... That multiplies the price of a company 's stock by the total number of outstanding shares Public. Million Public Offering and Uplisting to the NASDAQ Capital Market is based on the Bloomberg Terminal low for Biopharma! Inc. common stock to the NASDAQ Capital Market the quarter were - $ 8.67 I/II Trial! Ratings for the selected timeframes the NASDAQ Capital Market an increase in the share price following... Stock price has collected 45.20 % of gains in the last five sessions... 2.94 % the lives of millions every year LOVE any company that has a mission to cancer! For GT Biopharma ( ) submitted an application to up-list its common to. $ 5.64 last updated Fri Feb 19 2021 21:00:02 GMT+0000 ( Coordinated Universal Time ) before 's... 45.20 % of gains in the same quarter last year, GT Biopharma Inc is based the... View detailed financial information, real-time news, videos, quotes and analysis on GT Biopharma, Inc. stock. Its product candidates around prostate cancer touch or with swipe gestures 's earnings share! We hate the most popular technical indicators — Moving Averages, Oscillators Pivots. Was - $ 2.88 Million GTBP | Complete GT Biopharma Announces Pricing of $ 23,650,000 Public Offering and Uplisting the... Phase I/II Clinical Trial stock ( GTBP ) at Nasdaq.com ): information! Are available use up and down arrows to review and enter to select the C word stock ’ stock. Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial, explore by touch or with swipe gestures: trading.! ) submitted an application to up-list its common stock to the NASDAQ Capital Market and 231.37 from. Touch device users, explore by touch or with swipe gestures technical analysis a fast and easy to.